Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01638390 · ClinicalTrials.gov registry record · Phase 1
Use of the VisuMax™ Femtosecond Laser
A Phase 1 study, sponsored by Carl Zeiss Meditec.
- Completed
- Registry status
- Phase 1
- Development phase
- 357
- Enrollment target
NCT01638390 is a Phase 1 study that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 357 participants.
The verdict
NCT01638390, a Phase 1 study, has completed, sponsored by Carl Zeiss Meditec.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 357 participants
- Enrollment target
Study Summary
The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equivalent) ≤ -8.25 D.
Interventions
- DEVICE Treatment with the VisuMax™ Femtosecond Laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01638390
The ClinicalTrials.gov registry entry for NCT01638390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carl Zeiss Meditec, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment with the VisuMax™ Femtosecond Laser is the first listed.
NCT01638390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01638390 about?
NCT01638390 is a clinical study titled "Use of the VisuMax™ Femtosecond Laser". The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equ...
What is the current status of trial NCT01638390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 357 participants. The study started on 2012-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01638390?
The interventions under investigation include: Treatment with the VisuMax™ Femtosecond Laser (DEVICE).
Who is sponsoring clinical trial NCT01638390?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.